Novo Nordisk A/S (NYSE:NVO) is Y Intercept Hong Kong Ltd's Largest Position

Y Intercept Hong Kong Ltd boosted its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 98.1% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 247,815 shares of the company's stock after buying an additional 122,734 shares during the period. Novo Nordisk A/S makes up approximately 1.2% of Y Intercept Hong Kong Ltd's investment portfolio, making the stock its largest holding. Y Intercept Hong Kong Ltd's holdings in Novo Nordisk A/S were worth $17,208,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Strategic Investment Solutions Inc. IL lifted its holdings in Novo Nordisk A/S by 2,727.3% in the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock valued at $27,000 after acquiring an additional 300 shares during the period. Copeland Capital Management LLC lifted its holdings in Novo Nordisk A/S by 184.8% in the first quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock valued at $27,000 after acquiring an additional 255 shares during the period. North Capital Inc. acquired a new position in Novo Nordisk A/S in the first quarter valued at approximately $27,000. Park Square Financial Group LLC acquired a new position in Novo Nordisk A/S in the fourth quarter valued at approximately $29,000. Finally, Transce3nd LLC acquired a new position in Novo Nordisk A/S in the fourth quarter valued at approximately $33,000. Hedge funds and other institutional investors own 11.54% of the company's stock.

Wall Street Analysts Forecast Growth

NVO has been the subject of a number of analyst reports. BNP Paribas started coverage on Novo Nordisk A/S in a report on Tuesday, April 15th. They issued an "underperform" rating for the company. Dbs Bank downgraded Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. Guggenheim downgraded Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. Hsbc Global Res raised Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. Finally, Wall Street Zen raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Saturday, June 14th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $112.00.

Novo Nordisk A/S Price Performance

NYSE NVO traded up $0.65 during mid-day trading on Friday, hitting $71.38. The stock had a trading volume of 4,249,277 shares, compared to its average volume of 9,171,735. The firm's 50 day moving average is $70.52 and its 200 day moving average is $73.88. Novo Nordisk A/S has a twelve month low of $57.00 and a twelve month high of $139.74. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.74 and a quick ratio of 0.56. The stock has a market capitalization of $318.70 billion, a price-to-earnings ratio of 21.13, a PEG ratio of 1.35 and a beta of 0.64.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.92. The company had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. Equities research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.